("Glucagon-Like Peptide 1 Receptor Agonists" OR "GLP-1 receptor agonist" OR "Semaglutide" OR "Liraglutide" OR "Dulaglutide" OR "Exenatide" OR "Albiglutide" OR "Efpeglenatide" OR "Cotadutide" OR "Lixisenatide") AND  ("Diabetes Mellitus, Type 2" OR "Type 2 Diabetes" OR "T2DM") AND  ("Cardiovascular Diseases" OR "Major Adverse Cardiovascular Events" OR "MACE" OR "myocardial infarction" OR "stroke" OR "cardiovascular death"). This evidence concerns the gene GLP1R and diabetes mellitus.